✦ LIBER ✦

Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: a randomised, open label, non-inferiority phase 3 trial

✍ Scribed by Barrett-Lee, Peter; Casbard, Angela; Abraham, Jacinta; Hood, Kerenza; Coleman, Robert; Simmonds, Peter; Timmins, Hayley; Wheatley, Duncan; Grieve, Robert; Griffiths, Gareth; Murray, Nick

Book ID: 122320546
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 497 KB
Volume: 15
Category: Article
ISSN: 1470-2045
DOI: 10.1016/S1470-2045(13)70539-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of 12-weekly versus

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

✍ Amadori, Dino; Aglietta, Massimo; Alessi, Barbara; Gianni, Lorenzo; Ibrahim, Ton 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 265 KB

405 POSTER Phase III trial of oral iband

405 POSTER Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparison of bone turnover markers

📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Phase III trial of oral ibandronate and

Phase III trial of oral ibandronate and intravenous zoledronic acid in breast cancer patients with bone metastases: comparative bone turnover marker and safety data

✍ J.-J. Body; Lichinitser; S. Tjulandin; B. Bergström 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 269 KB

AOSOP6 Results from the 2-year open-labe

AOSOP6 Results from the 2-year open-label extension treatment phase of a pivotal phase 3 study of denosumab in patients with breast cancer and bone metastases previously treated with zoledronic acid or denosumab

✍ A.T. Stopeck; A. Lipton; M. Martín; J-J. Body; A. Paterson; G.G. Steger; K. Tonk 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 42 KB